中国民康医学
中國民康醫學
중국민강의학
MEDICAL JOURNAL OF CHINSEE PEOPLE HEALTH
2014年
19期
27-28
,共2页
驰欣杰%尹大维%苏醒%荣维君%王永顺%王雪梅
馳訢傑%尹大維%囌醒%榮維君%王永順%王雪梅
치흔걸%윤대유%소성%영유군%왕영순%왕설매
依达拉奉%血栓通%脑梗死
依達拉奉%血栓通%腦梗死
의체랍봉%혈전통%뇌경사
Edaravone%Xueshuantong%Cerebral infarction
目的:观察依达拉奉联合血栓通治疗脑梗死的临床疗效。方法:回顾性分析200例脑梗死患者临床资料,将其分为观察组和对照组,观察组采用依达拉奉联合血栓通治疗,对照组采用依达拉奉治疗。分析两组患者治疗前后神经功能缺失评分( NIHSS)及治疗4周后的疗效。结果:观察组与对照组患者治疗4周后的NIHSS评分均显著降低,且观察组治疗前后评分变化显著高于对照组,差异具有统计学意义(P<0.05)。结论:依达拉奉联合血栓通治疗脑梗死的临床疗效显著,值得临床推广。
目的:觀察依達拉奉聯閤血栓通治療腦梗死的臨床療效。方法:迴顧性分析200例腦梗死患者臨床資料,將其分為觀察組和對照組,觀察組採用依達拉奉聯閤血栓通治療,對照組採用依達拉奉治療。分析兩組患者治療前後神經功能缺失評分( NIHSS)及治療4週後的療效。結果:觀察組與對照組患者治療4週後的NIHSS評分均顯著降低,且觀察組治療前後評分變化顯著高于對照組,差異具有統計學意義(P<0.05)。結論:依達拉奉聯閤血栓通治療腦梗死的臨床療效顯著,值得臨床推廣。
목적:관찰의체랍봉연합혈전통치료뇌경사적림상료효。방법:회고성분석200례뇌경사환자림상자료,장기분위관찰조화대조조,관찰조채용의체랍봉연합혈전통치료,대조조채용의체랍봉치료。분석량조환자치료전후신경공능결실평분( NIHSS)급치료4주후적료효。결과:관찰조여대조조환자치료4주후적NIHSS평분균현저강저,차관찰조치료전후평분변화현저고우대조조,차이구유통계학의의(P<0.05)。결론:의체랍봉연합혈전통치료뇌경사적림상료효현저,치득림상추엄。
Objective:To observe clinical efficacy of Edaravone combined with Xueshuantong in treatment of cerebral infarc-tion. Methods:A retrospective analysis of the clinical data of 200 cases with cerebral infarction was done. All patients were divided in-to observation group and control group, wherein observation group was treated with Xueshuantong combined with Edaravone, while con-trol group was treated with Edaravone. National institute of health stroke scale ( NIHSS) scores before and after the treatment and the efficacy 4 weeks after the treatment were analyzed. Results:4 weeks after the treatment, the NIHSS scores of observation group and control group both significantly decreased. The NIHSS scores of observation group were significantly higher than those of control group before and after the treatment, and the differences were statistically significant (P<0. 05). Conclusions: Edaravone combined with Xueshuantong in the treatment of cerebral infarction has significant clinical effects, can effectively relieve symptoms, and is worthy of promotion.